arrow
N

Naureen Starling

royal marsden nhs foundation trust
H指数:43
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Management of colorectal cancer in older adults: an expert panel recommendation to guide daily clinical practice

老年结直肠癌的管理:专家小组建议以指导日常临床实践

2026-05-190
PRE
Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma—UK Tertiary Cancer Centre Experience

对于 borderline 可切除和局部晚期胰腺腺癌的术前新辅助治疗——英国三级癌症中心的经验

Cancers
IF4.4
2026-05-160
OA
Correction: Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma

更正:围手术期氟尿嘧啶、亚叶酸钙、奥沙利铂和多西他赛给药对局部晚期食管胃腺癌术后生存的影响

2025-12-190
OAAI
A Phase III study of perioperative dostarlimab in patients with dMMR/MSI-H resectable colon cancer: AZUR-2 study design

AZUR-2研究设计:一项关于围手术期 dostarlimab 用于 dMMR/MSI-H 可切除结肠癌患者的 III 期研究

2025-12-011
PRE
A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)

一项针对未治疗的II期/III期dMMR/MSI-H局部晚期直肠癌患者的多塔利单抗单药治疗的二期、单臂、开放标签研究(AZUR-1)

2025-02-210
OAAI
Precision Oncology: A Global Perspective on Implementation and Policy Development
2025-01-010
OA
Maintenance capecitabine plus ramucirumab after first-line platinum-based chemotherapy in advanced oesophagogastric adenocarcinoma (OGA): Final analysis from the PLATFORM trial

在晚期食道胃腺癌(OGA)中,在一线铂类为基础的化疗后进行卡培他滨联合雷莫芦单抗的维持治疗:PLATFORM试验的最终分析

2024-09-011
PRE
Maintenance durvalumab after fi rst-line chemotherapy in patients with HER2-negative advanced oesophago-gastric adenocarcinoma: results from the randomised PLATFORM study
2024-07-010
OAAI
Tissue-Free Liquid Biopsies Combining Genomic and Methylation Signals for Minimal Residual Disease Detection in Patients with Early Colorectal Cancer from the UK TRACC Part B Study

来自UK TRACC B部分研究的结合基因组和甲基化信号的无组织液体活检,用于早期结直肠癌患者的最小残留疾病检测

2024-06-122
OAAI